Physician profile
Nutan Bhaskar
NPI 1922269604
$3,375.42
in general payments reported to CMS, 2019-2025
23 companies · $422 in 2025
The $422 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.02 · 2020: $479 · 2021: $748 · 2022: $817 · 2023: $632 · 2024: $218 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,173 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,172.68 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,234.58 | 2020-2025 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $444.14 | 2020-2025 | Ofev, Jascayd |
| Astrazeneca Pharmaceuticals LP | $358.77 | 2020-2024 | Fasenra, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $203.50 | 2020-2023 | Glassia |
| Insmed, INC. | $198.72 | 2021-2025 | Arikayce, Brinsupri |
| Mallinckrodt Hospital Products INC. | $192.98 | 2020-2023 | Acthar |
| Regeneron Healthcare Solutions, INC. | $84.71 | 2022-2024 | Dupixent |
| Ani Pharmaceuticals, INC. | $78.42 | 2022-2024 | Purified Cortrophin Gel |
| Mylan Specialty L.P. | $77.17 | 2019-2023 | Yupelri |
| Verona Pharma, INC. | $60.49 | 2025 | Ohtuvayre |
| Actelion Pharmaceuticals US, INC. | $60.07 | 2020-2023 | Uptravi, Opsumit |
| Genentech USA, INC. | $54.82 | 2022-2023 | Xolair |
| Grifols USA, LLC | $50.32 | 2021-2022 | |
| Advanced Respiratory, INC | $46.69 | 2020-2021 | |
| United Therapeutics Corporation | $44.40 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $33.65 | 2024 | Fetroja |
| Bayer Healthcare Pharmaceuticals INC. | $29.70 | 2021 | |
| Genzyme Corporation | $28.19 | 2022-2023 | |
| Mallinckrodt Enterprises LLC | $22.47 | 2019 | |
| Inogen, INC. | $22.32 | 2022 | |
| Boston Scientific Corporation | $17.83 | 2021 | |
| Csl Behring | $16.82 | 2019 | |
| Philips North America LLC | $14.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nutan Bhaskar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.